Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Net Cash Flow for 14 consecutive years, with -$246.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 436.61% year-over-year to -$246.0 million; the TTM figure through Mar 2026 stood at $47.8 million (up 173.28% YoY), while the FY2025 annual figure was $248.0 million, up 851.52% from the prior year.
• Net Cash Flow declined to -$246.0 million in Q1 2026 per RARE's latest filing, from $222.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $368.5 million in Q2 2024 and bottomed at -$331.3 million in Q3 2024.
• Historically, Net Cash Flow has averaged -$7.1 million across 5 years, with a median of $7.7 million in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 2164.18% in 2024 and fell as far as 1068.89% in 2024.
• Ultragenyx Pharmaceutical's Net Cash Flow stood at -$260.1 million in 2022, then soared by 153.59% to $139.4 million in 2023, then plunged by 81.25% to $26.1 million in 2024, then soared by 749.94% to $222.1 million in 2025, then plunged by 210.75% to -$246.0 million in 2026.
• Business Quant data shows RARE's Net Cash Flow at -$246.0 million in Q1 2026, $222.1 million in Q4 2025, and $25.8 million in Q3 2025.